Berber Ilhami, Diri Halit, Erkurt Mehmet Ali, Aydogdu Ismet, Kaya Emin, Kuku Irfan
Division of Hematology, Department of Hematology, Faculty of Medicine, Medical School, Inonu University, 44280 Malatya, Turkey.
Department of Internal Medicine, Medical School, Inonu University, 44280 Malatya, Turkey.
Adv Hematol. 2014;2014:297057. doi: 10.1155/2014/297057. Epub 2014 Jun 11.
Introduction. Different ferric and ferrous iron preparations can be used as oral iron supplements. Our aim was to compare the effects of oral ferric and ferrous iron therapies in women with iron deficiency anaemia. Methods. The present study included 104 women diagnosed with iron deficiency anaemia after evaluation. In the evaluations performed to detect the aetiology underlying the iron deficiency anaemia, it was found and treated. After the detection of the iron deficiency anaemia aetiology and treatment of the underlying aetiology, the ferric group consisted of 30 patients treated with oral ferric protein succinylate tablets (2 × 40 mg elemental iron/day), and the second group consisted of 34 patients treated with oral ferrous glycine sulphate tablets (2 × 40 mg elemental iron/day) for three months. In all patients, the following laboratory evaluations were performed before beginning treatment and after treatment. Results. The mean haemoglobin and haematocrit increases were 0.95 g/dL and 2.62% in the ferric group, while they were 2.25 g/dL and 5.91% in the ferrous group, respectively. A significant difference was found between the groups regarding the increase in haemoglobin and haematocrit values (P < 0.05). Conclusion. Data are submitted on the good tolerability, higher efficacy, and lower cost of the ferrous preparation used in our study.
引言。不同的三价铁和二价铁制剂可作为口服铁补充剂使用。我们的目的是比较口服三价铁和二价铁疗法对缺铁性贫血女性的影响。方法。本研究纳入了104名经评估诊断为缺铁性贫血的女性。在进行评估以检测缺铁性贫血潜在病因时，病因被发现并得到治疗。在检测到缺铁性贫血病因并治疗潜在病因后，三价铁组由30名接受口服琥珀酸铁蛋白片（每日2次，每次40毫克元素铁）治疗的患者组成，第二组由34名接受口服甘氨酸硫酸亚铁片（每日2次，每次40毫克元素铁）治疗3个月的患者组成。对所有患者在开始治疗前和治疗后进行了以下实验室评估。结果。三价铁组血红蛋白和血细胞比容的平均增加值分别为0.95克/分升和2.62%，而二价铁组分别为2.25克/分升和5.91%。两组之间在血红蛋白和血细胞比容值的增加方面存在显著差异（P<0.05）。结论。提交了关于我们研究中使用的二价铁制剂耐受性良好、疗效更高且成本更低的数据。
